about
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsMeasures of viral load using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals.Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, MalawiSupporting Option B+ scale up and strengthening the prevention of mother-to-child transmission cascade in central Malawi: results from a serial cross-sectional study.Effect of cytomegalovirus infection on breastfeeding transmission of HIV and on the health of infants born to HIV-infected mothers.Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding.Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women.Thiamin and Riboflavin in Human Milk: Effects of Lipid-Based Nutrient Supplementation and Stage of Lactation on Vitamer Secretion and Contributions to Total Vitamin Content.Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants.Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.Maternal or infant antiretroviral drugs to reduce HIV-1 transmissionAntiretroviral therapy provided to HIV-infected Malawian women in a randomized trial diminishes the positive effects of lipid-based nutrient supplements on breast-milk B vitaminsDelayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding.Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxisIncorporating Acute HIV Screening into Routine HIV Testing at Sexually Transmitted Infection Clinics, and HIV Testing and Counseling Centers in Lilongwe, Malawi.Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trialRole of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: the BAN studyChanges in soluble transferrin receptor and hemoglobin concentrations in Malawian mothers are associated with those values in their exclusively breastfed, HIV-exposed infants.Plasma and breast-milk selenium in HIV-infected Malawian mothers are positively associated with infant selenium status but are not associated with maternal supplementation: results of the Breastfeeding, Antiretrovirals, and Nutrition study.Effects of community-level bed net coverage on malaria morbidity in Lilongwe, Malawi.Estimation of Plasmodium falciparum Transmission Intensity in Lilongwe, Malawi, by Microscopy, Rapid Diagnostic Testing, and Nucleic Acid Detection.Maternal and Breastmilk Viral Load: Impacts of Adherence on Peripartum HIV Infections Averted-The Breastfeeding, Antiretrovirals, and Nutrition Study.The effects of a lipid-based nutrient supplement and antiretroviral therapy in a randomized controlled trial on iron, copper, and zinc in milk from HIV-infected Malawian mothers and associations with maternal and infant biomarkers.RTS,S/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi.Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays.Effect of Postnatal HIV Treatment on Clinical Mastitis and Breast Inflammation in HIV-Infected Breast-feeding Women.Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.Prevalence of Asymptomatic Parasitemia and Gametocytemia in HIV-Infected Children on Differing Antiretroviral Therapy.Effects of concurrent exposure to antiretrovirals and cotrimoxazole prophylaxis among HIV-exposed, uninfected infants.Discordance between Self-Reported Contraceptive Use and Detection of Exogenous Hormones among Malawian Women Enrolling in a Randomized Clinical Trial.Cotrimoxazole Prophylaxis Associated With Reduced Anemia Hazard in HIV-Exposed Infants in a Malaria-Endemic Setting.Low absolute neutrophil counts in African infants.1000Effect of Cytomegalovirus Infection on Breastfeeding Transmission of HIV and on the Health of Infants Born to HIV-infected Mothers.Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 TransmissionPredictors of Perinatal HIV Transmission Among Women Without Prior Antiretroviral Therapy in a Resource-Limited Setting: The BAN StudyEffect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial
P50
Q28278852-046CB871-CE84-4209-8C50-350967AA35B5Q33813587-D6FA6F33-9680-45C8-8D6C-7A035DCB7141Q33990216-BF89064E-5175-44BC-B7E6-8E620B5C78E3Q35743290-63184ADD-2CE1-47BA-870A-4D7BD73C8369Q35825670-7BCE6B91-13A4-49FA-BE83-41182201EA9BQ35863995-0132D6E6-BAAC-44BF-A665-AF46835BC563Q35894292-AFBC3ECF-2E59-4D0F-8719-40D4CED1FD47Q35926307-BBE2D734-E23E-42D6-854B-CCF243656D38Q35975609-C8579E50-7D83-4B0A-A26F-536A27F5051CQ36080800-B079E88C-C3B9-4302-848C-337658F4BE16Q36218701-EF1BD1F1-91A9-4D00-A085-4EE68D3458E4Q36231035-414A4DA0-3932-49CE-AADE-3BA504DA44F4Q36316323-00D7CD88-437F-4123-8563-9324F1DE463FQ36335386-17144092-68B7-4B35-A140-EC108BD064EEQ36471547-F7BD442C-AB5F-44A4-91A4-07A77E6228D8Q36576458-5A37A436-B5FC-4FA1-B957-529665424D4AQ36866309-BA5FADAB-46C7-4744-A34D-388BC98C78E0Q37037065-9C88EE67-C78A-4BF9-A28A-32C9C65F12D8Q37590381-A87F1CEB-9A9D-45D8-B2CD-BB7CEE720FA4Q37636698-A676D1B2-2EFE-46D0-BA6A-1AF9D4EE765DQ37740953-24445AD7-DB83-4188-87E7-6086A44A1A31Q38850389-AA8B81A8-7842-4017-954B-1F47A2C57814Q39186563-D1752E12-8A75-4C5A-91E4-5718FA00935DQ40076034-81C89FEF-5C1E-499D-AF86-C047D8E6F64FQ40095307-9411C065-3106-4976-8D04-E603D931BE3BQ40178574-9FA30C7A-1EDF-4EA3-8C0D-68FB92A64453Q40226580-9C728DF7-0D74-427D-99E0-4ED450BD2C05Q40330558-8F864CC6-547B-4E59-AAA7-A936E507F34BQ42638889-B97A76EB-98FB-42C2-81B3-51FD5B43352BQ46178209-C70D1091-76F6-49B0-96EC-6B97EDBB311DQ46272544-E20CAECB-8F04-41F3-B5FE-80F6E6546B95Q46749807-18A71877-1823-40EC-AAB4-866E4E9DFAB9Q47112239-26E5BC88-758B-4F40-B6E9-7DEB4BA465D5Q53609099-A54088D1-4A68-46DB-8786-2CEAE48DA55CQ55421090-8112451D-5C67-4495-80E1-844F230ADDCCQ57950932-FBA9A0B9-49F6-4CFD-8984-B3915D3F93C0Q58098188-67592052-9B0D-406F-8735-22E13F7856E5Q58774718-0381B64E-9EF5-4289-AA9B-CB8EF59EBDFC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gerald Tegha
@ast
Gerald Tegha
@en
Gerald Tegha
@es
Gerald Tegha
@nl
type
label
Gerald Tegha
@ast
Gerald Tegha
@en
Gerald Tegha
@es
Gerald Tegha
@nl
prefLabel
Gerald Tegha
@ast
Gerald Tegha
@en
Gerald Tegha
@es
Gerald Tegha
@nl
P106
P31
P496
0000-0001-8582-3302